RxDoctor Payments Data

Ashok Modh, MD

Pulmonary Disease · Tampa, FLNPI 1578592556

Payments from drug & device makers

$14,419in general payments, 2019–2025

Across 689 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$2K
  • Harmony Biosciences LLC$1K
  • Boehringer Ingelheim$958
  • Jazz Pharmaceuticals Inc.$878
  • Takeda Pharmaceuticals U.S.A., Inc.$872
  • plus $6K from 35 others

What the payments were for

  • Consulting fees$1501%
  • Food & beverage$14,17898%
  • Education$911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,419 in reported general payments places this provider in the 70th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$356,042
Medicare patients
574
Services billed
3,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate62$802,641
Trelegy ElliptaFluticasone/Umeclidin/Vilanter395$452,090
XywavSodium,calcium,mag,pot Oxybate11$178,302
Dupixent PenDupilumab31$115,854
Breztri AerosphereBudesonide/Glycopyr/Formoterol95$110,040
Stiolto RespimatTiotropium Br/Olodaterol Hcl119$95,656
SymbicortBudesonide/Formoterol Fumarate177$66,321
Spiriva RespimatTiotropium Bromide69$58,217
Breo ElliptaFluticasone/Vilanterol68$39,903
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr55$31,565
Combivent RespimatIpratropium/Albuterol Sulfate44$25,768
Albuterol Sulfate HfaAlbuterol Sulfate576$22,392
Fluticasone-SalmeterolFluticasone Propion/Salmeterol104$20,855
Wixela InhubFluticasone Propion/Salmeterol64$18,047
EliquisApixaban14$15,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$958$982,282294 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$2,822$532,890535 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,582$176,361272 claims
PfizerEliquis$241$15,70114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →